MASTERINVEST Kapitalanlage GmbH Takes $530,000 Position in Bristol Myers Squibb Company $BMY

MASTERINVEST Kapitalanlage GmbH acquired a new position in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,194 shares of the biopharmaceutical company’s stock, valued at approximately $530,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Life Cycle Investment Partners Ltd bought a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $34,406,000. Lazard Asset Management LLC boosted its position in shares of Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after acquiring an additional 368,193 shares during the last quarter. Axxcess Wealth Management LLC grew its holdings in shares of Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after purchasing an additional 21,196 shares in the last quarter. Callan Family Office LLC bought a new stake in Bristol Myers Squibb in the second quarter worth $3,575,000. Finally, BlackRock Inc. raised its stake in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Insider Buying and Selling

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.05% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. JPMorgan Chase & Co. upped their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Guggenheim reiterated a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Truist Financial reissued a “buy” rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Stock Down 0.5%

Shares of NYSE BMY opened at $66.62 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The firm has a 50-day simple moving average of $61.76 and a two-hundred day simple moving average of $59.68. The company has a market cap of $136.09 billion, a P/E ratio of 14.67, a PEG ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period last year, the company earned $1.46 EPS. Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.